DTIL

Precision BioSciences, Inc. (DTIL) ESG Analysis Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 5.8 (Moderate)

DTIL’s environmental profile appears neutral versus peers because its gene-editing model is less emissions-intensive than manufacturing-heavy biotech, though lab energy use still creates footprint exposure.

The company’s R&D intensity is high relative to revenue, which can support lower direct operating emissions than scaled industrial peers, but peer biotech firms face similar laboratory impacts.

No disclosed environmental controversies or material regulatory breaches were provided, limiting downside versus peers, yet the absence of detailed sustainability disclosure weakens relative transparency.

Environmental risk is mainly indirect through supply-chain and facility energy use, which is broadly comparable to small-cap biotech peers rather than a clear advantage.

Social

Score:

DTIL’s social positioning is constrained by high stock-based compensation to revenue, which can pressure employee alignment and retention relative to better-capitalized peers.

The company’s research-focused model supports scientific talent attraction, but peer biotech firms often offer stronger scale, making DTIL’s workforce resilience less differentiated.

No material product-safety or patient-harm issues were provided, which avoids a peer-level social penalty, but limited disclosure reduces confidence in stakeholder management.

As a development-stage biotech, DTIL’s social impact is concentrated in employee and research practices, where it appears broadly average rather than leading versus peers.

Governance

Score:

DTIL’s governance profile is mixed because leverage is manageable, but the debt-to-equity ratio still leaves it less conservative than stronger peer balance sheets.

Stock-based compensation at 17.4% of revenue suggests meaningful dilution pressure, which is a common biotech issue but remains a governance drag versus disciplined peers.

The company’s capital allocation appears research-heavy, which is appropriate for biotech, yet the lack of provided disclosure on board oversight limits relative governance confidence.

No severe governance controversy was provided, but the combination of dilution and leverage keeps DTIL below better-governed peers with tighter capital discipline.

Overall Score

Score:

DTIL ranks as a middle-tier ESG name versus peers because it avoids major controversies, but disclosure depth and capital-discipline metrics are not clearly superior.

Score Driver: The Decisive Factor Is Average-To-Below-Average Governance And Disclosure Quality Relative To Peers, Which Offsets Otherwise Neutral Environmental And Social Exposure.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Precision BioSciences, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →